TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q

被引:3
|
作者
Garding, Angela [1 ,2 ]
Bhattacharya, Nupur [1 ,3 ]
Haebe, Sarah [1 ]
Mueller, Frederike [4 ]
Weichenhan, Dieter [5 ]
Idler, Irina [1 ]
Ickstadt, Katja [4 ]
Stilgenbauer, Stephan [6 ]
Mertens, Daniel [1 ,6 ]
机构
[1] Univ Ulm, DKFZ Heidelberg, Cooperat Unit Mech Leukemogenesis, D-89069 Ulm, Germany
[2] Inst Mol Biol, Mainz, Germany
[3] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
[4] Tech Univ Dortmund, Dept Stat & Biometry, Dortmund, Germany
[5] DKFZ Heidelberg, Dept Epigen & Canc Risk Factors, Heidelberg, Germany
[6] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany
关键词
KINASE-ACTIVITY; B-CELLS; EXPRESSION; METHYLATION; ACTIVATION; REGULATOR; SIGNALS;
D O I
10.3324/haematol.2012.070623
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukemia is characterized by the accumulation of B cells that are resistant to apoptosis. This resistance is induced by pro-survival stimuli from the microenvironment. TCL1 and ATM are central to the pathogenesis of the disease and associated with more aggressive disease. Their protein products have recently been shown to physically interact in leukemic cells and to impact on NF-kappa B signaling, which is a key regulator of apoptosis. In the present study we show that TCL1 and ATM are significantly co-expressed and up-regulated in malignant cells compared to non-malignant B cells, and that expression of TCL1 is partially deregulated by aberrant DNA-methylation. In addition, complex external stimuli induce essentially similar TCL1 and ATM time-course kinetics. In line with a coordinative regulation of NF-kappa B signaling by TCL1, its knockdown induced apoptosis in primary leukemia cells. These findings suggest that both genes functionally cooperate to modulate similar apoptosis-related cellular pathways.
引用
收藏
页码:269 / 273
页数:5
相关论文
共 50 条
  • [1] Insulin Receptor Activation in Deletion 11q Chronic Lymphocytic Leukemia
    Brown, Jennifer R.
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2605 - 2607
  • [2] The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia
    Stankovic, Tatjana
    Skowronska, Anna
    LEUKEMIA & LYMPHOMA, 2014, 55 (06) : 1227 - 1239
  • [3] Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion
    Sembries, S
    Pahl, H
    Stilgenbauer, S
    Döhner, H
    Schriever, F
    BLOOD, 1999, 93 (02) : 624 - 631
  • [4] TCL1 expression in chronic lymphocytic leukemia correlates with the intensity of 11q deletions and ZAP-70
    Rassenti, Laura
    Huynh, L.
    Basak, G. W.
    Ghia, E. M.
    Dyke, D. Van
    Heerema, N.
    Zahrieh, D.
    DalCin, P.
    Dell'Aquila, M. L.
    Koduru, P.
    Byrd, J. C.
    Kay, N. E.
    Rai, K. R.
    Brown, J. R.
    Wierda, W. W.
    Greaves, A. W.
    Kipps, Thomas J.
    BLOOD, 2007, 110 (11) : 616A - 616A
  • [5] The significance of deletion architecture, ATM mutational status and genomic complexity in 11q deleted Chronic Lymphocytic Leukaemia
    Rose-Zerilli, Matthew
    Parker, H.
    Parker, A.
    Rodriguez, A.
    Chaplin, T.
    Wade, R.
    Gardiner, A.
    Collins, A.
    Young, B. D.
    Stankovic, T.
    Oscier, D. G.
    Strefford, J. C.
    JOURNAL OF MEDICAL GENETICS, 2012, 49 : S45 - S45
  • [6] ATM Gene Point Mutation and Frameshift Mutation Are Found In High-Risk, Untreated Chronic Lymphocytic Leukemia Patients with Interstitial Deletion of Chromosome 11q and Uniparental Disomy of Chromosome 11q
    Schichman, Steven A.
    Han, Jennifer H.
    Saldivar, Juan-Sebastian
    Stone, Annjanette
    Winters, Maria
    Carter, Weleetka
    Frederick, Lori
    Viswanatha, David S.
    Zent, Clive S.
    BLOOD, 2010, 116 (21) : 1003 - 1003
  • [7] Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion
    Austen, Belinda
    Skowronska, Anna
    Baker, Claire
    Powell, Judith E.
    Gardiner, Anne
    Oscier, David
    Majid, Aneela
    Dyer, Martin
    Siebert, Reiner
    Taylor, A. Malcolm
    Moss, Paul A.
    Stankovic, Tatjana
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) : 5448 - 5457
  • [8] Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities
    Mittal, Amit K.
    Hegde, Ganapati V.
    Aoun, Patricia
    Bociek, Robert G.
    Dave, Bhavana J.
    Joshi, Avadhut D.
    Sanger, Warren G.
    Weisenburger, Dennis D.
    Joshi, Shantaram S.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2007, 20 (04) : 461 - 469
  • [9] Chemoimmunotherapy May Overcome the Adverse Prognostic Significance of 11q Deletion in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Tsimberidou, Apostolia-Maria
    Tam, Constantine
    Abruzzo, Lynne V.
    O'Brien, Susan
    Wierda, William G.
    Lerner, Susan
    Kantarjian, Hagop M.
    Keating, Michael J.
    CANCER, 2009, 115 (02) : 373 - 380
  • [10] BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion
    Del Giudice, Ilaria
    Bonina, Silvia
    Marinelli, Marilisa
    Cafforio, Luciana
    Raponi, Sara
    Boldrini, Eloise
    Bonafede, Alexia
    Tavolaro, Simona
    Ilari, Caterina
    Messina, Monica
    Chiaretti, Sabina
    Mauro, Francesca Romana
    Piciocchi, Alfonso
    Orlando, Sonia Maria
    Rigolin, Gian Matteo
    Cuneo, Antonio
    Rossi, Davide
    Gaidano, Gianluca
    Guarini, Anna
    Foa, Robin
    BLOOD, 2014, 124 (21)